Diagnostic preparations 1311
Contraindications
Contraindicated in individuals with known
hypersensitivity to iothalamic acid salts and
in those with anuria.
care considerations
• Person should receive a low residue diet
for the day preceding the procedure. A laxa
tive should also be given the day before the
procedure unless contraindicated.
• Fluids may be restricted 12–15 hours prior
to the procedure.
• Should be used cautiously in individuals
with advanced renal disease or phaeo
chromocytoma.
• Premedicationwith antihistaminesmay be
indicated in individuals with known history
of allergy and hypersensitivity reactions.
• Closely monitor individual for devel
opment of anaphylactic reaction. Ensure
emergencymanagement equipment avail
able and in correct working order.
• Closely monitor blood pressure through
out the procedure.
• Monitor vital signs and renal function
closely following procedure.
• Assess mental status.
• Ensure safety if the person is lightheaded.
Patient teaching
• Advise person to report any adverse
effects.
• Advise person to take care when standing
up or getting out of bed due to potential
dizziness.
• Advise person that delayed effects may
impact on safety when driving or operating
machinery.
meglumine iotroxate
Biliscopin
Pregnancy risk category NR
Use in sport: Permitted
Available form
Solution for injection:
105 mg/mL in 100 mL
Indications & dosages
➤
Radiological examination of hepatic and
biliaryductsandgallbladder—
Adults:
Individualised according to
individual factors and nature of X-ray.
Action
Non-ionic iodinated radiographic contrast
medium for hepatic, biliary duct and gall
bladder examination.
Route Onset
Peak
Duration
IV
Immediate Unknown Unknown
Adverse reactions
CNS:
altered speech,
coma
,
convulsions
,
dizziness, headache,
status epilepticus
,
somnolence, tremor.
CV:
alterations in heart rate, blood pressure,
cardiac rhythm;
cardiac arrest
; flushing;
ventricular fibrillation and collapse
.
ENT:
altered hearing.
Eye:
conjunctivitis, photophobia, swollen
eyelids, visual changes.
GI:
abdominal pain, diarrhoea, nausea, pale
stool, salivation, vomiting.
GU:
dark urine,
renal failure
, uricosuria.
Hepatic:
elevated liver enzymes and serum
bilirubin.
Psychiatric:
agitation, amnesia, confusion,
restlessness.
Respiratory:
altered respiratory rate,
asthma,
bronchospasm
, cough, dyspnoea,
laryngeal spasm
,
pulmonary oedema
,
respiratory arrest
, respiratory distress.
Skin:
angio-oedema
,erythema,exanthema,
flushing, itching, pruritus, urticaria.
Other:
altered body temperature,
ana
phylaxis
, hypersensitivity reaction, local
pain, oedema.
Interactions
Drug-drug.
Metformin/biguanides:
Potential
transient impairment of renal function
with possible lactic acidosis. Should be
discontinued 48 hours prior to and for 48
hours after procedure.
Interleukin-2:
Increased risk of delayed
reactions. Monitor closely.
